Glucagon-like peptide-1-based therapy (Exenatide, Liraglutide, Sitagliptin, Januvia, Saxagliptin, Onglyza) is gaining widespread use for type 2 diabetes, although there are concerns about risks for pancreatitis and pancreatic and thyroid cancersToo much noise about small benefits with background of many unanswered questions.Peter C. Butler, MD, from the University of California, Los Angeles, and colleagues express alarm regarding the potential long-term cancer risk associated with use of incretin-based glucose-lowering agents. Although, the GLP-1--based therapies arrived in clinical practice with much fanfare and anticipation.Michael A. Nauck has received consulting fees or-and honoraria for membership in advisory boards or-and honoraria for speaking from
1. Amylin Pharmaceuticals, Inc., San Diego, California;
2. AstraZeneca, Mjölndal, Sweden;
3. Berlin-Chemie AG-Menarini, Berlin, Germany;
4. Boehringer Ingelheim, Ingelheim, Germany;
5. Bristol-Myers Squibb EMEA, Rueil-Malmaison, France;
6. Diartis Pharmaceuticals, Inc., Redwood City, California;
7. Eli Lilly & Co., Indianapolis, Indiana;
8. F. Hoffmann-LaRoche Ltd., Basel, Switzerland;
9. GlaxoSmithKline LLC, King of Prussia, Pennsylvania;
10. Intarcia Therapeutics, Inc., Hayward, Calfornia;
11. Lilly Deutschland GmbH, Bad Homburg, Germany;
12. MannKind Corp., Danbury, Connecticut;
13. Merck Sharp & Dohme GmbH, München, Germany;
14. Merck Sharp & Dohme Corp., New Jersey; Novartis Pharma AG, Basel, Switzerland;
15. Novo Nordisk A-S, Bagsværd, Denmark;
16. Novo Nordisk Pharma GmbH, Mainz, Germany;
17. Sanofi Pharma, Bad Soden-Taunus, Germany; Takeda, Deerfield, Illinois;
18. Versartis, Sunnyvale, California;
19. and Wyeth Research, Collegeville, Pennsylvania;
20. including reimbursement for travel expenses in connection with the above-mentioned activities.
